2014
DOI: 10.1111/dom.12280
|View full text |Cite
|
Sign up to set email alerts
|

Mortality risk with sulphonylureas compared to metformin

Abstract: Current clinical guidelines in the USA and the UK recommend first-line glucose-lowering treatment with metformin monotherapy for glucose control in type 2 diabetes, where not contraindicated. Consequently, the proportion of people treated with sulphonylureas is decreasing. The purpose of this commentary is to discuss the risks and benefits associated with sulphonylurea monotherapy versus metformin monotherapy and the evidence that, in comparison with metformin, sulphonylureas cause increased harm to people wit… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
12
0
1

Year Published

2015
2015
2020
2020

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 20 publications
(15 citation statements)
references
References 82 publications
2
12
0
1
Order By: Relevance
“…In addition, sulfonylurea prescriptions were also associated with higher basal insulin persistence, which is controversial to No. of Pages 8 p r i m a r y c a r e d i a b e t e s x x x ( 2 0 1 5 ) xxx-xxx 7 recent findings [21,22]. Finally, older age was associated with better basal insulin persistence in the present study, which is confirming previous studies [13].…”
Section: Discussionsupporting
confidence: 91%
“…In addition, sulfonylurea prescriptions were also associated with higher basal insulin persistence, which is controversial to No. of Pages 8 p r i m a r y c a r e d i a b e t e s x x x ( 2 0 1 5 ) xxx-xxx 7 recent findings [21,22]. Finally, older age was associated with better basal insulin persistence in the present study, which is confirming previous studies [13].…”
Section: Discussionsupporting
confidence: 91%
“…However, many of the medications available to treat hyperglycemia in diabetes have no effect on cardiovascular risk or may have a theoretical concern for exacerbating cardiovascular risk factors and/or cardiovascular disease itself. 321328 While lowering glucose concentrations will ameliorate immediate symptoms of hyperglycemia (polyuria, polydipsia, and weight loss) and longer term microvascular disease, there is less evidence for targeting HbA 1c to lower cardiovascular risk.…”
Section: Atherosclerotic Cardiovascular Risk Reduction In Diabetesmentioning
confidence: 99%
“…As guidelines governing management of type 2 diabetes increasingly advocate use of metformin as first line treatment (e.g. the recent European Renal Best Practice guideline supporting use of metformin in tapered doses in patients with renal insufficiency) our results underscore the clinical importance of discontinuation of metformin in cases of acute illness, particularly as continuance of treatment in patients with acute renal impairment could lead to metformin accumulation with induction of direct tubular damage and injury aggravation.…”
Section: Discussionmentioning
confidence: 73%
“…The efficacy of initiating metformin in type 2 diabetes is well documented . Guidelines governing management of patients with type 2 diabetes increasingly advocate use of metformin in spite of mild, moderate, and recently, also severe renal impairment . Treatment with metformin has been associated with AKI in vivo, and may be dose‐dependently associated with acid‐base imbalance and AKI .…”
Section: Introductionmentioning
confidence: 99%